Soleno Therapeutics reported early sales figures for Vykat XR, the first approved treatment for hyperphagia in Prader-Willi syndrome. The medicine’s net revenue for Q2 2025 is forecast between $31 million to $33 million, surpassing Wall Street estimates. Since its U.S. approval in March, demand has grown rapidly, with 646 patient start forms initiated by 295 physicians. Soleno concurrently raised $200 million in a stock offering to support the commercial launch. Market analysts anticipate Vykat XR’s peak sales may reach $2.5 billion globally, highlighting the rare disease market’s commercial potential despite the high cost of therapy.